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Summary. Malignant cells in haemopoietic autografts can 
contribute to post-transplant relapse. Engraftment of mye­
loma patients with CD34+ peripheral blood progenitors 
selected from total autografts reduces the number of tumour 
cells infused by 2'7-4-5 logs. Residual tumour cells detected 
in CD34+ selected cells may be due to selection impurity or 
the existence of malignant CD34+ progenitors. In three 
patients we evaluated the CD34 purity and tumour load of 
total autografts, CD34+ progenitors selected with immuno- 
magnetic beads and highly purified CD34+ progenitors 
obtained in two rounds of selection (combining magnetic 
with flow cytometry activated cell sorting) to determine the 
cause of residual tumour cells in CD34 selections.
Using allele-specific oligonucleotides (ASO) complemen­
tary to the unique Ig heavy chain sequence (CDRIII region) 
of the malignant clone, semi-quantitative ASO-PCR was 
capable of detecting one malignant cell in 104- 1 0 5 normal 
white blood cells. Selection of CD34+ cells from bone 
marrow (BM) with approximately 20% malignant plasma
cells resulted in a 1-4 log reduction of tumour burden. Using
two-colour flow-cytometry we observed CD34~, BB4 +
malignant plasma cells contaminating this CD34 selection. 
Prior to sorting, peripheral blood cell autografts (PBCA) 
contained approximately 0*1% malignant cells. Selection of 
>99% pure CD34+ cells using immunomagnetic beads 
(Dynal) resulted in an approximate 2 log reduction of 
malignant cells, but residual tumour cells were still 
detectable. ASO-PCR detected no malignant cells in 
>99*9% pure CD34+ peripheral blood progenitors obtained 
with two rounds of selection (combining magnetic with {low
Keywords: PBCA, myeloma, CD 34, immunoglobulin, ASO- 
PCR.
Autologous bone marrow transplantation as a treatment for 
multiple myeloma patients frequently results in early relapse 
(Barlogie et a l  1987; Gore et al, 1989; Jagannath et al,
1990). These relapses can result from residual tumour cells 
in the autologous graft as was shown for AML (Brenner et al, 
1993), follicular lymphomas (Gribben et al, 1991) and CML 
(Deisseroth et al, 1994). Using selected CD34+ peripheral 
blood progenitors rather than total peripheral blood cell 
autografts (PBCA) reduces the number of tumour cells 
infused by 2*7-4*5 logs (Schiller et al, 1995). In myeloma 
some residual tumour cells have been detected in selections 
of CD34+ cells (Takishita et al, 1994; Belch et a l 1994; 
Bersagel et al, 1994; Schiller et al, 1995), suggesting either
Correspondence: Dr E. J. B. M. Mensink, Deparment of Internal 
Medicine, Division of Haematology, University Hospital Nijmegen, 
P.O. Box 9101, 6500HB Nijmegen, The Netherlands.
the existence of malignant CD34 1 progenitors or impurity of 
the CD34 selection. If malignant CD.34'* s
contributing to post-transplant relapse exist in myeloma, 
CD34 selection would be inadequate as a purging strategy 
for myeloma autografts. On the other hand, If residual 
tumour cells are due to impurity of the Cl) 54 selection, better 
CD34 selection methods are needed. To determine the cause 
of residual tumour cells in selections of CD34 f 
quantified the tumour load and evaluated CD 3 4 purity of 
total autografts, CD34+ progenitors selected with immuno­
magnetic beads and CD34+ progenitors purified with two 
rounds of selection (combining magnetic and How cytometry 
activated cell sorting).
Using oligonucleotide primers complementary to the 
unique immunoglobulin heavy chain CDRIII sequence of 
the malignant clone, we developed tumour-specillc PCRs 
capable of detecting one tumour cell in a background of 104
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normal cells. Using these sensitive PCRs we show that 
multiple myeloma PBCA contain about 0*1% tumour cells 
and that immunomagnetic bead selection of CD34+ cells 
results in an approximate 2 log depletion of tumour cells. 
Residual tumour cells in CD34 selections were due to 
contaminating CD34-negative cells.
with May Griinwald Giemsa (MGG) and differential mor-
phology of 200 nucleated was scored by two
MATERIAL AND METHODS
Patients. All three patients (K, S and T) included in this 
study had stage III multiple myeloma according to Durie & 
Salmon (1975) and had been previously treated with 
alkylating agents and prednisone. Patients S and K subse­
quently received repeated courses of steroids with vincristine 
and doxorubicin administered by continous infusion (VAD). 
Patients T and S achieved partial remission but patient K was 
refractory to prior treatment. For all three patients 
peripheral blood stem cells were harvested after high-dose 
cyclophosphamide (7 g/m2) and G- or GM-CSF (patients T 
and K). Stem cells were re-infused after high-dose melphalan 
(140 mg/m2) and TBI (9 Gy).
Cell isolations. Bone marrow cells were obtained by 
aspiration from the sternum of the patients after informed 
consent. PBCA were collected in four to six aphereses 
procedures with a continuous flow cell separator (Fenwal CS 
3000, Baxter Healthcare, Deerfield, U.S.A.; Areman et al, 
1990). Cytospin preparations of BM and PBCA were stained
independent investigators. Cells were layered over Ficoll 
Hypaque and the mononuclear layer was collected after 
density centrifugation and washed in phosphate-buffered 
saline (PBS). These cells were cryopreserved at —196°C in 
small aliquots.
Cell sortings. The cryopreserved cells were thawed, washed 
and resuspended in RPMI 1640 supplemented with 10% 
FCS. More than 40 x 106 thawed cells were washed and 
resuspended in PBS with 1% BSA (PBSB) to a concentration 
of 107 cells/ml. CD34+ cells were selected according to the 
manufacturer’s protocol with M450 beads directly coated 
with ‘561’ antibody (Dynal). Bead to cell ratio was 1:2. After 
30 min incubation at 4°C with CD34 beads, a magnetic 
separation was performed. Selected cells were concentrated 
in 150 /¿I PBSB and detachment of beads was performed by 
adding 50 /¿I CD34 Detach-a-Bead (Dynal). After incubation 
for 1 h at room temperature, beads were magnetically 
separated from detached cells. Purity of CD34 selection 
was flow-cytometrically monitored. In brief, detached cells 
were washed twice and concentrated in 100 /d PBSB and 
incubated with a mixture of phycoerythrin (PE)-conjugated 
CD34 (HPCA-2, Becton Dickinson) and fluorescein isothyo- 
cyanate (FITC)-conjugated BB4 (Immuno Quality Products). 
As a control cells were labelled with IgGl-FITC/IgGl-PE. 
Flow cytometric analysis and FACS was performed with an
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Fig 1(a). Outline of the method used to develop ASO-PCR. Schematic representation of the rearranged heavy chain locus amplilied by CDR3 
primers.
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Fig 1(b). IgH CDR3 PCR products generated using consensus 
primers. The radioactive products are separated on a 6% non- 
denaturing polyacrylamide gel.
Epics Elite flow-cytometer (Coulter Corporation, Hialeah, 
U.S.A.) equipped with a 15 mW argon laser (488 nm). Cells 
were ilow-cytometrically sorted with a data rate of between 
1000 and 2000 cells per second into a PBSB foam layer on 
top of 100/il PBSB in 1ml Eppendorf vials. An aliquot of
each sorted fraction was re-analysed on the flow-cytometer 
to assess the purity. 50 jul of each sorted fraction was 
cytocentrifuged and stained with MGG to assess the 
morphology of sorted cells.
DNA extraction. DNA was extracted by making whole-cell 
lysates. If present, erythrocytes were lysed with NH4CI. The 
NH4CI was then washed away with PBS. Cells in PBS were 
transferred to Eppendorf tubes and pelleted in an Eppendorf 
centrifuge (5min, 400g  at 4°C). The supernatant was 
removed and the pellet loosened by vigorous rasping. The 
pellet of ^  10s cells was resuspended in PCR buffer 
supplemented with 0’5% NP40 and 0*5% Tween 20 to a
concentration of 104 cells/¡¿I. l / i l  of proteinase K (10 mg/ 
ml) was added for every 100 /il cell lysate. The cell lysate was 
incubated at 55°C for 1 h, after which the proteinase K was 
inactivated by a lOmin incubation at 95' C. When <  10s 
cells were available, pelleted cells were resuspended to a 
concentration of 10 cells //til. In those cases 1 //I of proteinase 
K (0* 1 mg/ml) was added for every 100 /¿l. Whole-ceil lysates 
were frozen at — 70°C. 10 /xl of cell lysate was used in each 
PCR.
Amplification of CDRIII using consensus primers. Whole-cell 
lysates were subjected to PCR in a 1 0 0 /tl PCR solution 
containing: 31 /¿m dNTP, 0*2 ¡A [a- u P]dCTP (Amersham 
International, Amersham, U.K., 30Q0Ci/mmol, lOmCi/ml), 
5 0 mM KCl, 1 0 mM Tris-HCl pH8*4, 0-0001% gelatine, 2*5 
Units Taq DNA polymerase (Life Technologies) and 30pmol 
of each consensus primer (Fig 2). Primers were synthesized 
on a 391A DNA synthesizer (Applied Biosystems, Warring­
ton, U.K.). PCR was performed for 35 cycles of 1 min 95°C, 
lm in  55°C and lm in  72°C, supplemented with a Anal 
10min extension at 72°C in a Perkin-Elmer - IM 
thermocycler. Radioactive products were 
6% non-denaturing polyacrylamide gel.
Analysis of CDRIII sequence. For direct 5
on a
stranded DNA was by
double-
chain
FR3 I CDR3 I FR4
Vcon
CTGTCGACACGGCCGTGTATTACTG
patient S DM1/DM2/DN1 DIR
ASO-probe
TTTGACTACTGGGGCCAAGGGAACCCT-JH4b
I
ASO
CTGTCGACACGGCCGTGTATTACTG TGTCGCC
patient K
ASO
ASO-probe
TCACTATTGGGGCCAAGGGAACCCT-JH4b
D21 /9 I
ASO-probe
CTGTCGACACGGCCGTGTATTACTG CGCGAG.
patient T
AACTGGTTCGACCCCTGGGGCCAAGGQAACCCT-JHSb
DXP4 I
GOTCACCGTCTCCTCAGGT- OJhcon
TTTTQ3AGGTCAGÆAA&J3AAAG“ OJhSi
Fig 2. DNA sequences of IgH VDJ junctions from predominant clones in myeloma BM and location of primers used 
end of the third framework region (FR3) and 5' end of the fourth framework region (FR4) are Indicated accordir _ 
boxed regions designate putative D and DIR sequences (Ichihara et al, 1988). The Jh gene used, the amount of trimming, and possible somatic 
mutations (bold capitals) are indicated based upon published sequences (Ravetch (’L al, 1981).
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termination method (Innis et al, 1988) in a 10-cycle PCR 
using 5pmol of one of the end-labelled CDRIII consensus 
primers (Fig 2) and 1 /¿I (lOng) template. CDRIII sequences 
were searched for homology (Yamada et al, 1991) with 
published DIR (Dh gene containing irregular spacer signals), 
D gene segments (Ichihara et al, 1988; Matsuda et al, 1990; 
Buluwela et al, 1988) and Jh gene segments (Ravetch et al, 
1981).
Tumour-specific PCR of patient samples. To achieve highest 
PCR specificity allele specific oligonucleotides (ASOs) were 
designed complementary to the CDRIII region with the 
highest variability amongst different B-cell clones (Fig 2). A 
non-radioactive amplification was performed essentially as 
described for CDRIII consensus PCR except for the use of 
30pmol 5'ASO primer instead of Vconsensus primer (Fig 2) 
and a dNTP concentration of 250 ¡jm. PCR products were 
separated on 2% agarose gel, transferred to nylon mem­
branes (Hybond N + ) and probed with end-labelled ASO 
probes under stringent conditions. Radioactive signals were 
visualized on X-ray film (Kodak) and quantified by densito- 
metrical scanning on a LKB laser densitometer. Allele- 
specific calibration curves were generated after serially 
diluting patient marrow DNA into PCR lysate buffer in 10- 
fold decrements, supplemented with normal white bood cell
4(NWBC) lysate to yield a concentration of 1<
PCR lysate buffer and 10s cells per PCR.
Statistical estimation of tumour load. Quantified PCR 
product is given in OD (optical density, arbitrary units). 
Least squares was used to lit a linear regression equation for 
In (OD) as a function of In (tumour fraction) for each patient. 
The number of tumour cells in patient samples and its 9 5 % 
Scheffe’s confidence interval was computed using this 
patient-specific linear regression equation (Billadeau et al,
1991).
82 m
ß2m
/32m
5'-CTAAACTTGTCCCGACCCTC primers. Size of the /32m 
PCR product was estimated on 2% agarose gels using a 
100 bp ladder (Pharmacia) as a reference.
RESULTS 
CDRIII sequencing
To determine the Ig heavy chain CDRIII sequence of the 
malignant clone we performed radioactive PCR using the 
consensus primers cujhcon and Vcon flanking the Ig CDRIII
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Fig 3. (a) ASO-PCR analysis of tumour cells in 
PBCA fractions of patient S. The dilutions of 
BM DNA samples used to obtain the 
calibration curve are shown on the left. CD 3 4 
pos columns represent duplicate PCRs of the 
same selection of CD34+ cells with 
immunomagnetic beads. An aliquot of this 
CD34+ selection was then subdivided by flow 
sorting. The columns CD34 pos, BB4 neg and 
CD34 pos, BB4 pos represent ASO-PCR results 
performed with DNA isolated from flow sorted 
CD34+ , BB4~ and CD34 + , BB4+ cells.
(b) Ethidium bromide stained 2% agarose gel 
showing /?2m control products of patient S 
DNA samples used in ASO-PCR.
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Fig 4. (a) ASO-PCR analysis of myeloma tumour in BM fractions of patient S. T 
curve are shown on the left. Sample description is as in Fig 3. 
from bone marrow samples that were depleted of CD34-positive cells, (b) Ethidium bromide stained 2% agarose 
products of patient S DNA samples used in ASO-PCR.
region (Fig la). Performing this PCR with a DNA template 
isolated from polyclonal B-cell compartments (NWBC) 
resulted in multiple PCR products differing in length and 
sequence. The use of DNA template isolated from multiple 
myeloma bone marrow samples (containing over 10% 
plasma cells) resulted in just one PCR product (Fig lb). 
Direct sequencing of these PCR products consistently 
revealed only one CDRIII sequence at different time points 
(before and after high-dose chemotherapy) in a patient’s 
disease.
Sensitivity of ASO-PCR to specifically detect malignant cells 
For each patient two allele-specific oligonucleotides (ASO) 
were synthesized (Fig 2). Using a 5' ASO and the ajhcon or 
o:Jh5i primer a PCR was developed that was specific for the 
malignant clone. ASO-PCR products were blotted and 
hybridized with a radiolabelled internal ASO-probe (Fig
preparations.
patient never
multiple myeloma patients. By serially diluting the DNA 
derived from myeloma bone marrow samples (containing 
> 30% plasma cells) in DNA derived from NWBC we were
detection of one tumour cell in 104- 1 0 5 normal white blood 
cells (Figs 3 and 4).
Quantification of malignant cells in myeloma autografts 
As a control we performed PCR with f i l m  primers on all 
samples tested in the tumour-specific PCRs. Only minor
s were
observed (Figs 3 and 4). We conclude that the DNA
© 1996 Blackwell Science Ltd, British Journal of Haematology 93: 613-622
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Fig 6. Flow cytometric analysis of cells obtained with CD34 immunomagnetic bead selection from bone marrow (a, b) and PBCA (c, d) of patient 
S. Analysis of forward and side scatter (a) and CD34 (PE) and BB4 (FITC) expression (b). For bone marrow as well as PBCA material Cl) 54 1, 
BB4~ cells in gate F and CD34 + , BB4+ cells in gate D were further purified by FACS. Purity of the CD34 1 , BB4 cellsort was monitored by How 
cytometric analysis of CD34 (PE) and BB4 (FITC) expression (d). The quadrant B indicates green and red fluorescence of IgC-PIi/IgO-FlTC control 
antibodies.
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preparation was of sufficient quality to allow PCR amplifica­
tion of each sample with comparable efficiency. ASO-PCR 
detected between 007%  and 0-17% malignant cells in PBCA 
in three patients in duplicate PCR experiments (Fig 5). 
Plasma cells were never detected in cytospin preparations of 
PBCA whereas in cytospins of bone marrow aspirates 2-5%  
plasma cells were found (results not shown).
Isolation o f CD34 + progenitors using immunomagnetic beads 
CD34+ cells were selected from PBCA and BM using
CD34 +-immunomagnetic beads (Dynal). Flow-cytometric 
analysis of detached cells, stained with CD34 phyco- 
erythrin showed that purity of CD34+ peripheral blood 
progenitor cells was always higher than 99% (Fig 6c). 
Using this procedure, PBCA or BM were depleted of 99% of 
the CD34 + cells and we consequently called these 
fractions CD34\ Tumour-specific ASO-PCR detected 
<0-002% malignant cells in CD34+ immunomagnetic 
bead preparations and 0-03-0-1%  malignant cells in 
CD34~ PBCA fractions (Figs 3 and 5a). Thus the majority 
of malignant cells were not selected with CD34 immuno­
magnetic beads and CD34 selection from PBCA using 
immunomagnetic beads (Dynal) reduced malignant cells 
with approximately 2 logs. Selection of CD34+ cells from 
bone marrow of patient T resulted in a 2-6 log reduction in 
tumour cells (Fig 5b). We used BM of patient S (who had 
progressed to plasma cell leukaemia) to test if, in bone 
marrow heavily infiltrated with malignant cells, the same 
reduction of tumour cells could be accomplished with 
CD34 selection. Flow-cytometric analysis of this BM 
sample stained with the plasma cell (PC) marker BB4- 
FITC (Pellat-Deceunynck et al, 1994) revealed 20-7% PC. 
In MGG-stained cytospins 22% PC were detected (results 
not shown). When the selected CD34+ cells were stained 
with BB4 and CD34, purity was higher than 75%. BB4 
PC (1%) were, however, contaminating this selection (Fig 
6b). Tumour-speciiic ASO-PCR detected 22*2% malignant 
cells in this BM aspirate of patient S and 25-7% in the 
CD34” fraction. In the CD34 + fraction 0-8% malignant 
cells were detected (Figs 4 and 5b). We conclude that 
selection of CD34+ cells from highly contaminated BM 
results in a 1*4 log reduction of tumour cells.
+
Isolation of CD34 + progenitors using immunomagnetic beads 
followed by flow cytometrically activated cell sorting (FACS) 
The selection of CD 3 4 + progenitors from BM of patient S was
contaminated with BB4+ PC (Fig 6b). Using FACS we sorted 
103 BB4 4 PC (Fig 6b, gate D) from CD34 immunomagnetic
bead fractions. Cytospin preparations of sorted BB4+ cells 
showed only cells with typical plasma cell morphology 
(results not shown). ASO-PCR showed that BB4 + PC belong 
to the malignant clone (Fig 4). Over 90% of the BB4+ cells 
were CD34 negative, suggesting that most plasma cells 
contaminate the CD 3 4 selections in a non-specific manner. If 
this were true it would mean that increasing the purity of 
CD34+ cells could further reduce the contamination of 
malignant cells. Highly purified CD34+ BM progenitors were 
obtained in two rounds of selection combining magnetic 
with flow cytometry activated cell sorting (Fig 6b, gate F).
Purity of these flow-sorted CD34'* cells was > 99-9%. ASO- 
PCR showed that a second round of purification with FACS 
results in a 2-3 log reduction of malignant cells (Figs 4 and 
5b). Flow-cytometric analysis of CD34+ immunomagnetic 
bead selections from PBCA of patients S and T showed 0*1% 
CD34+ , BB4+ cells but no CD34‘, BB4 +
sorted 105 CD 3 4 BB4 cells.
PC. Using FACS, we 
+ , BB4+ and 10s CD34 + ,
Purity of flow sorted CD34+ peripheral blood progenitors 
was > 99-9% (Fig 6d). ASO-PCR could not detect tumour 
cells in either of these fractions (Fig 3 and5a). Consequently 
malignant cells with a CD34+ progenitor phenotype were 
not detectable in PBCA of three patients and residual tumour 
cells detected in CD34 selections were due to contaminating 
CD34 negative myeloma cells.
DISCUSSION
In this study we showed that residual tumour cells in CD34 
selections of myeloma autografts are due to impurity. We 
used tumour-specific PCR, capable of detecting one malig­
nant cell in a background of .10s normal white blood cells. In 
accordance with other studies (Mariette et al, 1994; Bird et 
al, 1994) we found between 0-07% and 0-17% malignant 
cells in PBCA. CD34 selection using immunomagnetic beads 
resulted in an approximately 2 log depletion of malignant 
cells in myeloma PBCA of three patients. Even when highly 
contaminated BM (22% PC) was used for CD34 selection, a 
1-4 log reduction in tumour cells was achieved. Assuming 
that most tumour cells do not express the CD 3 4 marker, a 
log reduction in malignant cells is in agreement with the 2 
log increase of CD34+ cells achieved by CD34 selection. An 
additional advantage of autologous CD34 + transplants over 
total peripheral blood cell transplants is that fewer cells are 
needed, resulting in a 2 -7-4- 5 log reduction of malignant 
cells in clinical trials (Schiller et al, 1995).
Since the CD34 selection was not 1.00% pure we reasoned 
that positive ASO-PCR signals might result from contamina­
tion with CD34-negative cells. Starting with BM heavily 
infiltrated with plasma cells we showed that contaminating 
malignant plasma cells were the major cause of impurity in 
CD34 immunomagnetic beads selections. In those cases the 
purging of BB4 + PC in combination with CD 34 selection
2
using beads
tumour cell reduction. A contamination phenomenon was 
also reported by Vescio et al (1994). They found 
ASO-PCR signals when CD34 cells were collected 1’ 
with one round of selection using a 
column, whereas a second round of CD34 
FACS
suggested that residual tumour 
CD,34+ cells are malignant CD 34 ‘
*cHon with
m a
in of
progenitors (Takishita 
et al, 1994; Belch et al, 1994; Bersagel et al, 1994). Since no 
PCR data of preselected material are shown it cannot be 
excluded that the positive ASO-PCR signals Takashita et al 
(1994) report after having selected CD34 or CD20 cells from 
PB of myeloma patients with FACS arise from contamina­
tion, To prove that positive ASO-PCR signals in CD 34 
selections arise from contamination with CD .34-negative 
tumour cells not from malignant CD34 1
C5 1996 Blackwell Science Ltd, British Journal of Haematology 93: 613-622
Residual Myeloma Cells in CD34 Selection due to Impurity 621
performed a second round of CD34 selection with FACS 
resulting in > 99*9% pure CD 3 4 1 cells. We found a clearcut 
reduction of malignant cells with ASO-PCR when we
£
compared 10 CD 3 4 immunomagnetic bead selected cells 
with 105 highly purified CD34+ cells (isolated with two 
rounds of CD34 selection) in patients S and T. In 10s highly 
purified CD34+ cells from PBCA we were not able to detect 
malignant cells with ASO-PCR. These experiments show 
that ASO-PCR signals in CD34 selections arise from 
contamination with CD34-negative tumour cells.
Our results argue against the presence of malignant 
CD34+ precursors. One could reason, however, that 
malignant CD34+ stem cells that have yet to undergo Ig 
gene rearrangement or malignant pre B cells that could still 
undergo Vh replacements and somatic hypermutation could 
exist and escape detection by ASO-PCR. If such precursor 
cells exist, the plasma cell progeny should have an extremely 
diverse Ig gene sequence. However, after sequencing multi­
ple clones in each patient, Bakkus et al (1992) and Vescio et 
al (1993) found no evidence of intraclonal diversity. They 
concluded there was no ongoing somatic hypermutation. In 
addition, others found no evidence for ongoing Vh replace­
ments (Takishita et al, 1994). Therefore the scenario of a 
malignant pre-B-lymphocyte or stem cell as a precursor for 
malignant plasma cells is unlikely. It has been suggested that 
a change in the predominant tumour clone may occasion­
ally occur in multiple myeloma (Bird et al, 1994), resulting 
in tumour cells that are not detected by ASO-PCR. We 
detected the same monoclonal tumour population before 
and after peripheral blood cell transplantation without 
major additional clones appearing. We conclude that there 
was no clonal evolution in our patients and tumour cells are 
thus adequately quantified.
In summary, residual tumour cells detected in CD34 
selections are due to impurity. Removal of all tumour cells 
from the graft is not possible with CD34 selection protocols 
that are currently applied in clinical trials (Schiller et al, 
1995). We and others (Vescio et al, 1994), however, 
consistently achieved negative ASO-PCR signals with two 
rounds of CD 3 4 selection, or a combination of counterflow 
élutriation, treatment with phenylalanine methylester and 
flow sorting of CD34 + , Lin”, Thy+ stem cells (Gazitt et al, 
1995). Since purity of CD34 selection seems the most 
essential parameter in obtaining tumour-free autografts, we 
are currently evaluating the purity of different CD341 
isolation methods and their applicability in the clinical 
setting of autologous transplantation.
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